HealthBridge to Support Apligraf for Organogenesis BRAINTREE, Mass., Oct. 27 /PRNewswire/ -- HealthBridge, a reimbursement and product support services company, was selected by biotechnology company Organogenesis to manage the APLIGRAF(R) Reimbursement Support Center. Apligraf is used as a wound-healing therapy for the treatment of diabetic foot ulcers and venous leg ulcers. Organogenesis was the first company to develop and gain FDA approval for a mass-produced product containing living human cells. Through the APLIGRAF(R) Reimbursement Support Center, HealthBridge answers questions from patients and physicians' offices about insurance coverage. The goal is to simplify the process of securing reimbursement for APLIGRAF(R) while ensuring access to the drug for patients who need it. "We're excited about the opportunity to work with Organogenesis and support the APLIGRAF(R) Reimbursement Support Center," said John J. Seman, president & CEO of HealthBridge. "Providing reimbursement support to patients and physicians allows the physicians to focus on healing the patient, and the patient on getting well. We take the complexities out of the insurance system and enable the patient to receive their prescribed treatment." About HealthBridge HealthBridge is a dynamic, growth-oriented company offering services, which simplify the complexities of medical reimbursement. The company provides pharmaceutical, biotechnology and medical device companies with innovative reimbursement solutions that support product goals and educate physicians, payers and patients. HealthBridge is located in Braintree, Massachusetts. For more information, please visit http://www.healthbridgeinc.com/ or call 888.558.2850. Contact: Stacie Madden (781) 926-3614 DATASOURCE: HealthBridge CONTACT: Stacie Madden of HealthBridge, +1-781-926-3614, Web site: http://www.healthbridgeinc.com/

Copyright